Vaxcyte Inc
$ 58.07
-1.39%
07 Aug - close price
- Market Cap 8,641,122,000 USD
- Current Price $ 58.07
- High / Low $ 60.08 / 56.73
- Stock P/E N/A
- Book Value 20.76
- EPS -7.51
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.36 %
- 52 Week High 65.00
- 52 Week Low 29.50
About
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
Analyst Target Price
$109.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-24 | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-06 |
| Reported EPS | -1.97 | -2.3 | -1.8 | -1.56 | -1.22 | -1.04 | -1.0176 | -0.83 | -1.1 | -0.85 | -1.82 | -0.91 |
| Estimated EPS | -1.47 | -1.77 | -1.47 | -1.24 | -1.16 | -0.97 | -0.992 | -0.99 | -1 | -1.06 | -1.07 | -0.84 |
| Surprise | -0.5 | -0.53 | -0.33 | -0.32 | -0.06 | -0.07 | -0.0256 | 0.16 | -0.1 | 0.21 | -0.75 | -0.07 |
| Surprise Percentage | -34.0136% | -29.9435% | -22.449% | -25.8065% | -5.1724% | -7.2165% | -2.5806% | 16.1616% | -10% | 19.8113% | -70.0935% | -8.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCVX
2026-08-06 14:41:41
FMR LLC and Abigail P. Johnson have reported an amended beneficial ownership of Vaxcyte Inc. common stock through a Schedule 13G filing. FMR LLC now holds 20,798,906.96 shares, representing 14.4% of the class, with sole voting power over 18,886,452.19 shares and sole dispositive power over the full amount. Abigail P. Johnson also reports sole dispositive power over the same number of shares, amounting to 14.4% of the class.
2026-08-05 20:41:58
Vaxcyte reported its second-quarter 2026 results, showing $2,507.7 million in cash and investments and a net loss of $284.3 million. Research and development expenses increased to $267.9 million, driven by PCV program development. The company also provided updates on its clinical programs, including expected data readouts for VAX-31 adult and infant programs and the initiation of a Phase 1 study for VAX-A1.
2026-08-05 20:10:08
This SEC filing for Vaxcyte, Inc. (PCVX) is a Form 144, indicating a proposed sale of 17,000 shares of common stock with an aggregate market value of $935,000. The shares were acquired through the exercise of stock options on August 5, 2026, and are intended to be sold on NASDAQ. The filing details the transaction and affirms that the filer has no material adverse non-public information.
2026-08-05 19:41:58
Vaxcyte has reported its financial results for the second quarter of 2026 and provided a business update. The company is likely detailing its progress on clinical trials, financial performance, and future outlook in the biotechnology sector.
2026-08-05 19:41:57
Vaxcyte (Nasdaq: PCVX) announced its Q2 2026 financial results and provided a business update. The company reported approximately $2.5 billion in cash and anticipates topline safety and immunogenicity data from its VAX-31 adult Phase 3 OPUS-1 trial in Q4 2026, with further Phase 3 results expected in the first half of 2027. Vaxcyte also initiated a Phase 1 study for VAX-A1, a prophylactic vaccine for Group A Streptococcus, with data expected in the second half of 2027.
2026-08-04 04:39:51
Vaxcyte (PCVX) insider Andrew Guggenhime has filed a Form 144 to sell 10,000 shares of common stock through UBS Financial Services on August 3, 2026, with an indicated value of $539,900. This sale is connected to an exercise of stock options. Guggenhime has made similar sales in the past three months, including 10,000 shares on June 18, 2026, for $530,000 and another 10,000 shares on July 6, 2026, for $572,836.
